Ben, I agree that the progress here is slow and the communication could be better. No disagreement from me there. The PD1-Vaxx 1a trial completed enrolment in Jan 2022 and the combo trial started in June 2023 - a full 18 months between the two.
That said, the 1b trial spans 6 sites across 2 countries and involves a supply agreement with Roche. There are over 300 active trials with Atezolizumab alone. So, I don't think the amount of effort involved in that undertaking can be underestimated.
On the supposition piece, none of the communication gets better unless we shareholders start asking more questions, more often. I've started doing that given I have significantly increased my holding at these lower prices (where I first started i might add) and I want to be better informed.
GLTAH
IMU Price at posting:
5.3¢ Sentiment: Buy Disclosure: Held
(20min delay)